11月16~18日,2019美国心脏协会科学年会(AHA 2019)将在美国费城召开,今年会议热点包括最新科学专场,FIT /早期职业规划,前沿科学峰会,心血管临床护理研讨会以及摘要口头报告和壁报专场等。
编者按:11月16~18日,2019美国心脏协会科学年会(AHA 2019)将在美国费城召开,今年会议热点包括最新科学专场,FIT /早期职业规划,前沿科学峰会,心血管临床护理研讨会以及摘要口头报告和壁报专场等。届时,本刊进行现场同步报道,现将最新热点研究整理如下,以飨读者。
LBS.01 - Late Breaking Science I: Outside the Box: New Approaches to CVD Risk Reduction
November 16, 2019, 10:45 AM - 12:00 PM Main Event I
10:48 AM - 10:56 AM
The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF): Results in Nondiabetic Patients
达格列净预防心力衰竭不良结局的研究(DAPA-HF):在非糖尿病患者中的结果
11:06 AM - 11:14 AM
Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol - Results From the Phase 3 ORION-10 Trial
Inclisiran在ASCVD和LDL-C升高的患者中的安全性和有效性:ORION-10 III期试验结果
11:24 AM - 11:32 AM
The COLchicine Cardiovascular Outcomes Trial (COLCOT)
COLchicine心血管结局试验(COLCOT)
11:42 AM - 11:50 AM
Effect of?BET?Protein Inhibition With?Apabetalone?on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BET on MACE Trial
BET蛋白抑制剂Apabetalone对急性冠状动脉综合征和糖尿病患者心血管结局的影响-BET的MACE试验结果
LBS.02 - Late Breaking Science II: Results for the Ischemia Trials: To Intervene or Not to Intervene
November 16, 2019, 2:00 PM - 3:15 PM Main Event I
2:10 PM - 2:22 PM
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes
对比药物和侵入性方法治疗效果的国际研究:临床结果报告
2:22 PM - 2:29 PM
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Quality of Life Outcomes
对比药物和侵入性方法治疗效果的国际研究:生活质量报告
2:34 PM - 2:44 PM
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches- Chronic Kidney Disease (ISCHEMIA-CKD): Primary Results of Clinical Outcomes
对比药物和侵入性方法治疗效果的国际研究—慢性肾脏病(ISCHEMIA-CKD):临床结果
LBS.03 - Late Breaking Science III: Controversies in Contemporary Management of AS
November 16, 2019, 5:30 PM - 6:45 PM Main Event II
5:35 PM - 5:45 PM
Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcathether Aortic Valve Replacement to Optimize Clinical Outcomes (GALILEO) Trial: Primary Results
经导管主动脉瓣置换术后基于利伐沙班的抗栓策略与基于抗血小板策略的全球比较的优化临床结局(GALILEO)试验结果
5:50 PM - 6:00 PM
Randomized Clinical Trial Comparing a Rivaroxaban-Based Strategy With an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves (GALILEO-4D)
比较基于利伐沙班的策略和基于抗血小板的策略预防经导管主动脉瓣亚临床小叶血栓形成的随机临床试验(GALILEO-4D)
6:05 PM - 6:15 PM
Balloon-Expandable versus Self-Expandable TAVR on Paravalvular Regurgitation and 2-Year Mortality: A Propensity-Matched Comparison From the FRANCE-TAVI Registry
球囊扩张与自扩张TAVR对瓣周关闭不全和2年死亡率的影响:来自FRANCE-TAVI登记处的倾向匹配比较
6:25 PM - 6:35 PM
Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis
无症状重度主动脉瓣狭窄的早期手术与常规治疗
LBS.04 - Late Breaking Science IV: State of the Art Interventional Management for ACS Patients
November 17, 2019, 9:00 AM - 10:15 AM Main Event I
9:00 AM - 9:09 AM
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention for Acute Coronary Syndrome
替格瑞洛联合阿司匹林或单药应用在急性冠状动脉综合征冠状动脉介入治疗后高风险患者中的应用
9:13 AM - 9:22 AM
Colchicine in Percutaneous Coronary Intervention
秋水仙碱在经皮冠状动脉介入治疗中的作用
9:26 AM - 9:35 AM
Non-Culprit Lesion Plaque Morphology in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography (OCT) Substudy
ST段抬高型心肌梗死患者的非罪犯病变斑块形态:COMPLETE试验光学相干断层扫描(OCT)亚组研究结果
9:39 AM - 9:48 AM
One Year Outcomes of Coronary Angiography After Cardiac Arrest
心搏骤停后一年冠状动脉造影结果
9:52 AM - 9:59 AM
Mortality and Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Percutaneous Coronary Intervention With Impella? vs Intra-Aortic Balloon Pump
Impella? vs. IABP支持下伴心源性休克的急性心肌梗死患者行PCI治疗的死亡率和出血
9:59 AM - 10:06 AM
The Comparative Effectiveness and Costs of Impella vs. Intra-Aortic Balloon Pump in the United States
美国Impella与 IABP的疗效和成本比较
LBS.05 - Late Breaking Science V: Challenges in Heart Failure Management
November 17, 2019, 10:45 AM - 12:00 PM Main Event I
10:45 AM - 10:54 AM
Results From the Pediatric Heart Network’s Fontan Udenafil Exercise Longitudinal Trial
儿科心脏网络的Fontan Udenafil运动纵向试验结果
10:58 AM - 11:07 AM
Effect of Treatment According to Age in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF)
DAPA-HF试验(达格列净预防心力衰竭不良结局研究)中根据年龄进行治疗的效果
11:07 AM - 11:13 AM
Effect of Treatment on the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF)
DAPA-HF试验(达格列净预防心力衰竭不良结局研究)中有关堪萨斯城心肌病问卷的治疗效果
11:17 AM - 11:26 AM
LBCT: Effects of Sacubitril/Valsartan in Women Compared to Men With Heart Failure and Preserved Ejection Fraction
LBCT:与心力衰竭和射血分数保留的男性相比,沙库必曲/缬沙坦对女性的影响
11:26 AM - 11:35 AM
Effect of Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
沙库必曲/缬沙坦对心力衰竭患者射血分数的影响
11:39 AM - 11:49 AM
Putting It All Together: How to Use SGLT2 Inhibitors and ARNIs in Practice
如何在实践中使用SGLT2抑制剂和ARNIs
LBS.06 - Late Breaking Science VI: New Frontiers in Lipid Therapy
November 18, 2019, 9:00 AM - 10:15 AM Main Event I
9:00 AM - 9:10 AM
Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides (200-499mg/dl) on Statin Therapy (EVAPORATE Study)
二十碳五烯酸乙酯对他汀类药物治疗甘油三酸酯(200~499 mg/dl)升高的患者冠状动脉粥样硬化进展的影响(EVAPORATE研究)
9:24 AM - 9:32 AM
Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia - Results From the Phase 3 ORION-9 Trial
Inclisiran在杂合子家族性高胆固醇血症患者中的安全性和有效性—ORION-9 III期试验结果
9:32 AM - 9:38 AM
RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides
靶向载脂蛋白C-III的RNA干扰可致血浆甘油三酸酯进一步和长期减少
9:38 AM - 9:44 AM
RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects
靶向肝血管生成素样蛋白3的RNA干扰可使人类受试者血浆甘油三酸酯和LDL-C的减少时间延长
9:49 AM - 9:59 AM
Benefit of a Target LDL Cholesterol Less Than 70 mg/dl After an Ischemic Stroke of Atherosclerotic Origin, the Treat Stroke to Target Trial Results
动脉粥样硬化引起的缺血性卒中后目标LDL-C低于70 mg/dl的获益—TST试验结果